Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Sclerosis - Payer Insight: Update Bulletin [April 2017]

Product Code:
April Date:
April 2017

Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS); the impact of the launch delay of generic Copaxone 40mg/ml and potential steps that Teva could take to retain market share of its branded Copaxone; approaches to reimbursing Alkermes’ ALKS 8700 and opinions on ways by which Biogen could retain market share of Tecfidera.

Business Questions:

  • How do payers react to the recent approval of ocrelizumab?
  • How is ocrelizumab likely to be covered in the US?
  • How do US payers feel about ocrelizumab’s competitive pricing? Are there any apprehensions?
  • How do payers react to the delay in launch of generic Copaxone 40mg/ml?
  • According to payers, what can Teva do to retain its market share of branded Copaxone 40mg/ml?
  • According to payers, what can Biogen do to retain market share of Tecfidera?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved